№ lp_1_2_43220
File format: docx
Character count: 10255
File size: 101 KB
Year:
2018
Note:
Region / City
Subject:
Voice Alarm Systems
Document Type:
Certification Scheme
Organization:
BRE Global Ltd
Target Audience:
Manufacturers of voice alarm control and indicating equipment
Description:
Certification scheme for voice alarm control and indicating equipment, ensuring compliance with specified standards for fire detection and alarm systems.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2023
Jurisdiction:
Australia
Type of document:
Legislative determination and reporting standard
Issuing authority:
Australian Prudential Regulation Authority
Legal basis:
Financial Sector (Collection of Data) Act 2001
Related legislation:
Life Insurance Act 1995; Acts Interpretation Act 1901; Legislation Act 2003
Reporting standard identifier:
LRS 112.0
Subject matter:
Capital base determination for life insurance companies
Regulated entities:
Life insurance companies and friendly societies
Commencement date:
26 May 2023
Application date:
Reporting periods ending on or after 1 July 2023
Registration authority:
Federal Register of Legislation
Signatory:
Michael Murphy, General Manager – Chief Data Officer (Acting)
Reporting frequency:
Quarterly and annual
Submission method:
Electronic submission to APRA
Amends or revokes:
Determination No. 24 of 2023
Year:
2022
Region / City:
Australia
Subject:
Pharmacology, Pharmaceutical Benefits Scheme (PBS)
Document Type:
Submission
Organization / Institution:
Sanofi-Aventis Australia Pty Ltd
Author:
Not specified
Target Audience:
Medical practitioners, healthcare professionals
Period of validity:
Not specified
Approval Date:
3 June 2022
Date of Changes:
Not specified
Contextual Description:
A regulatory submission detailing the request for listing of dupilumab in new forms for treating severe atopic dermatitis and uncontrolled severe asthma in pediatric patients under the PBS.
Year:
2025
Region / City:
Athens, Greece
Topic:
NR_IoT_NTN_Bands
Document Type:
Information
Source:
Moderator (Aalyria)
Audience:
Technical experts, telecom industry professionals
Period of Validity:
Not specified
Approval Date:
Not specified
Last Modified Date:
Not specified
Jurisdiction:
Florida, United States
Document type:
Criminal jury instruction
Subject matter:
Sexual battery offenses
Statutes cited:
§§ 794.011, 794.021, 794.022, 775.0862, 800.04, 784.03, 784.011, 784.021, 784.041, 784.045, 777.04, Florida Statutes
Instruction number:
11.4
Adopting authority:
Supreme Court of Florida
Year adopted:
1981
Amendment dates:
1987; 1995; 2003; 2015; 2016; November 20, 2020; December 15, 2021; December 21, 2022
Effective statutory terminology update:
October 1, 2022
Case law referenced:
Lakey v. State (2013); Phillips v. State (2018); Flores v. State (2024); Apprendi v. New Jersey (2000)
Covered conduct:
Sexual battery without force
Age criteria:
Victim 12 years or older; defendant age varies by subsection
Special provisions:
School authority figure enhancement; lesser-included offenses
Authoring body:
Florida Standard Jury Instructions in Criminal Cases
Year:
2021
Region / City:
Australia
Topic:
Atopic dermatitis treatment, medication submission
Document Type:
Submission report
Organization / Institution:
Sanofi-Aventis Australia Pty Ltd
Author:
Sanofi-Aventis
Target Audience:
Medical professionals, regulatory authorities
Action Period:
Ongoing treatment evaluation
Approval Date:
17 August 2021
Modification Date:
Not specified
Background:
Dupilumab registration history
Clinical Claim:
Dupilumab has superior efficacy compared to standard care for children with severe atopic dermatitis
Episodicity:
Chronic
Severity:
Severe
Condition:
Atopic dermatitis
PBS Indication:
Chronic severe atopic dermatitis
Prescriber Type:
Medical practitioners, dermatologists, clinical immunologists
Treatment Phase:
Initial, continuing
Population Criteria:
Children aged 6 to 11 years, specific weight ranges
Comparator:
Placebo
Outcomes:
EASI-75, IGA 0 or 1 at Week 16, improvement in itch score
Dosing:
Tiered by body weight
Cost:
$1,754.28–$3,380.91
Price:
Published price for maximum quantity
Form:
Pre-filled syringe
Medical Information:
Dupilumab 300 mg/2 mL, 200 mg/1.14 mL
Note:
Comparator
Standard of care (Placebo)
Source:
PBAC submission
Year:
2023
Region / city:
Bering Sea, Aleutian Islands, Gulf of Alaska
Topic:
Environmental Impact, Fishery Management, Electronic Monitoring
Document type:
Environmental Assessment
Agency / Institution:
National Marine Fisheries Service, North Pacific Fishery Management Council
Author:
National Marine Fisheries Service
Target audience:
Policy makers, environmental agencies, fishery managers
Action period:
2023-ongoing
Approval date:
2023
Amendment date:
Not specified
Note:
Year
Topic:
Music Technology
Document Type:
Educational Activity
Target Audience:
Students
Year:
2020
Region / City:
Massachusetts
Topic:
Medicaid, Personal Needs Allowance, Nursing Facilities, Chronic Disease and Rehabilitation Hospitals
Document Type:
Bulletin
Organization:
Executive Office of Health and Human Services
Author:
Daniel Tsai, Assistant Secretary for MassHealth
Target Audience:
Nursing Facilities and Chronic Disease and Rehabilitation Inpatient Hospitals
Effective Period:
March 2020
Approval Date:
March 2020
Amendment Date:
N/A
Year:
2023
Meeting:
3GPP TSG RAN WG1 Meeting #114
Location:
Toulouse, France
Dates:
21 August 2023 – 25 August 2023
Source:
Moderator (Intel Corporation)
Agenda item:
9.5.1.1
Document for:
Discussion and Decision
Subject:
SL positioning reference signal (SL PRS)
Release:
Rel-18
Working Item:
Expanded and improved NR positioning
Related groups:
RAN1, RAN2, RAN3, RAN4
Frequency ranges:
FR1, FR2
Organizations mentioned:
OPPO; CATT; Intel Corporation
Year:
2019
Topic:
Personal Development, Self-Reflection
Document Type:
Podcast Episode
Author:
Dr. Katie Linda
Target Audience:
Individuals interested in personal development, goal setting
Action Period:
2019
Approval Date:
December 2018
Modification Date:
Not mentioned
Note:
Context
Note:
Year
Topic:
Drainage Systems, Trench Drains, Construction Materials
Document Type:
Technical Specification
Organization / Institution:
MultiDrain Systems, Inc.
Target Audience:
Engineers, Contractors
Duration:
140 minutes
Total marks:
114
Subject:
Physics
Topic:
Simple harmonic motion and waves
Question format:
Multiple-choice
Number of questions:
22
Marks per question:
1 mark (where indicated)
Physical quantities referenced:
period, frequency, amplitude, displacement, velocity, acceleration, energy, phase difference, spring constant, gravitational acceleration
Units used:
mm, m, s, kg, J, Hz, km s–1, rad
Motion types:
simple harmonic motion, damped oscillation, forced vibration, resonance
Systems described:
simple pendulum, mass-spring system, oscillating particle, wave propagation
Assessment type:
Homework questions
Year:
2004
Region / city:
Christchurch
Topic:
Building regulations, change of use
Document type:
Notice
Institution:
Christchurch City Council
Author:
Not specified
Target audience:
Building owners, agents, council authorities
Period of validity:
Not specified
Approval date:
Not specified
Amendment date:
Not specified
Year:
2024
Region / City:
Australia
Topic:
Severe Atopic Dermatitis Treatment, Pharmaceutical Pricing
Document Type:
Proposal
Organization:
Sanofi-Aventis Australia Pty Ltd
Author:
Sanofi-Aventis
Target Audience:
Healthcare professionals, policymakers, pharmaceutical stakeholders
Effective Period:
December 1, 2024 onwards
Approval Date:
11 June 2024
Modification Date:
March 2024
Context:
Proposal to delist dupilumab (Dupixent®) from PBS for severe atopic dermatitis treatment, addressing cost-effectiveness and price reduction negotiations with PBAC.